Catalyst Event
Eli Lilly and Co (LLY) · Other
From Akros SCHK HK-US Biotech Index (ASHUBIO)
4/10/2026, 12:00:00 AM
FDA decision for orforglipron, a once-daily oral GLP-1 drug for obesity, is expected. Approval would represent a major expansion of Lilly's obesity franchise into a more convenient oral treatment.
Korean Translation
1일 1회 경구용 GLP-1 비만 치료제 후보물질 올포글리프론(orforglipron)에 대한 FDA 승인 결정이 예상됨. 승인 시 릴리의 비만 프랜차이즈가 편리한 경구 치료제로 확장되는 중요한 계기가 될 것임.
Related Recent Events
CSPC Pharmaceutical Group Ltd (1093) · Other
Final dividend of HKD 0.15 per share for FY2025 (total HKD 0.29, +11.5% YoY) with ex-dividend date June 24, 2026; low importance as dividend increases typically result in minor positive price adjustments scheduled.
6/24/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
High importance is estimated due to the potential for significant price volatility for Pfizer's Q1 2026 earnings release and conference call, scheduled.
5/5/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release and conference call scheduled; typically results in moderate price movement.
4/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q1 2026 earnings release and conference call scheduled.
4/30/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Q1 2026 earnings release and conference call for 2026-04-30, estimated to have a low impact of ~1-2% based on historical trends, scheduled.
4/30/2026, 12:00:00 AM
Regeneron Pharmaceuticals Inc (REGN) · Earnings Release
Regeneron is scheduled to report its first quarter 2026 financial and operating results on 2026-04-29. Importance is Medium as earnings typically drive significant price movement, scheduled.
4/29/2026, 12:00:00 AM